TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07093801: Real-world Experience of Lutetium (177Lu) Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer, an Observational, National, Multicenter, Prospective Cohort Study (PLU4REAL).

Sponsor: Novartis Pharmaceuticals · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 300 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$508,200

Rescue Site Savings

+$323,400

Unlock Full NCT07093801 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07093801 Rescue Dossier →